Deprescribing Tamsulosin in Older Men

• Status: Active, not recruiting
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is a pilot 12-week randomized, placebo-controlled N-of-1 deprescribing trial among older men receiving chronic tamsulosin therapy for lower urinary tract symptoms attributed to benign prostatic hyperplasia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Treatments: Tamsulosin

Criteria

Inclusion Criteria:

• Urology patient at UCSF

• Must own Android or iPhone smartphone, tablet, or computer

• Taking tamsulosin for urinary-related symptoms

• Able to speak and read English

• Male 55-80 years old of age at telephone screening.

• Written informed consent (and assent when applicable) obtained from subject or subject' s legal representative and ability for subject to comply with the requirements of the study.

• Willing to receive electronic PERSONAL daily intake surveys for 3 months

• Willing to self-report urinary symptom or medication side effect data at specified frequency.

• Have home WiFi access.

• Patients with h/o prostate cancer may be enrolled but is not required

• Patients with h/o kidney stones may be enrolled but is not required

Exclusion Criteria:

• Taking tamsulosin for <12 months.

• International Prostate Symptom Score <5 or >25

• Current participation in any other mobile app-based clinical study.

• Planning to relocate from area within the study duration.

• Impaired vision that could limit the use of the mobile apps (participant-reported)